MedTrace Logo

A Diagnostic for the Early Detection of Bladder Cancer

NCT05347342 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 173

Last updated 2026-02-03

No results posted yet for this study

Summary

To improve upon the non-invasive detection of bladder cancer by further validating a multiplex ELISA assay directed at a bladder cancer-associated diagnostic signature in voided urine samples of patients with a high risk of developing bladder cancer.

Conditions

Sponsors & Collaborators

  • Nonagen Bioscience Corporation

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • VA Long Beach Healthcare System

    collaborator FED

  • Cedars-Sinai Medical Center

    lead OTHER

Principal Investigators

  • Hideki Furuya · Cedars-Sinai Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-29
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05347342 on ClinicalTrials.gov